Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population; anaemia is a frequent complication. Inadequate erythropoietin production and absolute or functional iron deficiency are the major causes. Accordingly, the current treatment is based on iron and erythropoiesis stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Locatelli, Francesco, Minutolo, Roberto, De Nicola, Luca, Del Vecchio, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645314/
https://www.ncbi.nlm.nih.gov/pubmed/36350500
http://dx.doi.org/10.1007/s40265-022-01783-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645314/
https://www.ncbi.nlm.nih.gov/pubmed/36350500
http://dx.doi.org/10.1007/s40265-022-01783-3

Ejemplares similares